Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652253 | 0.85 | ERN1 (0.59) | ERN1NFE2L2MEN1KMT2ATDP1 | |
| SCHEMBL16933848 | 0.85 | NFE2L2 (0.50) | ERN1NFE2L2ALDH1A1IKBKBHPGD | |
| SCHEMBL28966086 | 0.84 | MEN1 (0.46) | ERN1MEN1KMT2ATDP1LMNA | |
| SCHEMBL1990145 | 0.83 | ERN1 (0.53) | ERN1NFE2L2MEN1KMT2ATDP1 | |
| SCHEMBL95708 | 0.79 | ERN1 (0.50) | ERN1NFE2L2MEN1KMT2ATDP1 | |
| SCHEMBL30035291 | 0.76 | KMT2A (0.48) | ERN1MEN1KMT2ATDP1LMNA | |
| SCHEMBL9560195 | 0.76 | KMT2A (0.48) | ERN1MEN1KMT2ATDP1LMNA | |
| SCHEMBL8702525 | 0.75 | ERN1 (0.53) | ERN1NFE2L2MEN1KMT2ATDP1 | |
| SCHEMBL13708150 | 0.75 | ERN1 (0.52) | ERN1NFE2L2MEN1KMT2ATDP1 | |
| SCHEMBL16790878 | 0.75 | ALDH1A1 (0.50) | ERN1MEN1KMT2ATDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357809-B2 | Acyclic IKur inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120094983-A1 | ACYCLIC IKUR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| US-7915410-B2 | Acyclic IKur inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| CN-101277939-A | Acyclic ikur inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-10-01 | — | — | CN | disclosed |
| EP-1922311-A2 | ACYCLIC IKUR INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20070082909-A1 | Acyclic Ikur inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-12 | — | — | US | disclosed |
| WO-2007030582-A2 | ACYCLIC IKUR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082909-A1 | Acyclic Ikur inhibitors | KCNH2, KCNJ2, KCNH3 | ERN1 362/4885NFE2L2 2562/4885MEN1 3458/4885 |
| US-20120094983-A1 | ACYCLIC IKUR INHIBITORS | KCNH2, KCNJ2, KCNH3 | ERN1 362/4885NFE2L2 2562/4885MEN1 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.